PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-35.35%
Cash & equivalents declining -35.35% while CRVO's grows 130.91%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-35.35%
Below half of CRVO's 130.91%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
45.32%
Higher Other Current Assets Growth compared to CRVO's zero value, indicating worse performance.
-30.67%
Below half of CRVO's 118.06%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-13.90%
≥ 1.5x CRVO's -9.06%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.03%
Less than half of CRVO's 10.88%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
-10.42%
≥ 1.5x CRVO's -0.19%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-28.48%
Below half of CRVO's 48.86%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-10.38%
Less than half of CRVO's 149.05%. David Dodd sees a more disciplined AP approach or lower volume.
1404.09%
Higher Short-Term Debt Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
10.38%
Higher Deferred Revenue (Current) Growth compared to CRVO's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
-3.56%
Less than half of CRVO's 41.28%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-18.88%
Less than half of CRVO's 54.45%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-5.58%
Less than half of CRVO's 48.46%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-2.25%
0.5-0.75x CRVO's -4.27%. Martin Whitman is wary of weaker retention or lower profitability.
-5.49%
Higher AOCI Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-43.19%
Below half CRVO's 48.94%. Michael Burry sees potential underperformance in building shareholder capital.
-28.48%
Below half CRVO's 48.86%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
14.13%
Less than half of CRVO's -8.41%. David Dodd sees less overall debt expansion vs. competitor.
40.09%
Less than half of CRVO's -137.31%. David Dodd sees better deleveraging or stronger cash buildup than competitor.